TJ Jia
Gründer bei Octagon Capital Advisor/ Private Equity
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Lihua Zheng | M | - |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million. | - |
Bing Yan | M | - |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million. | - |
Junyuan Jerry Wang | M | - |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million. | - |
Cyrus Mozayeni | M | 49 |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | - |
Keting Chu | M | - |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | - |
William J. Rutter | M | - |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | - |
Michael Murray | M | - |
BVF Partners LP
BVF Partners LP Investment ManagersFinance BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts. | 11 Jahre |
Zhengwei Zhu | M | - |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million. | - |
Abraham Bassan | M | 39 |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | 3 Jahre |
Xiaohang Tong | M | - |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million. | - |
Wei Xu | M | 55 |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million. | - |
Alon Lazarus | M | 49 |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | - |
Kang Xie | M | 61 |
Sun Yat-Sen University
| 23 Jahre |
Zhu Ming Chen | M | 58 |
Sun Yat-Sen University
| 22 Jahre |
Hai Fa Sun | M | 68 |
Sun Yat-Sen University
| 24 Jahre |
Benjamin Yerxa | M | 58 |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | - |
Fei Li | M | 66 |
Sun Yat-Sen University
| 22 Jahre |
Soraya Bekkali | M | - |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | - |
Bin Lin | M | 62 |
Sun Yat-Sen University
| 23 Jahre |
Jin Song Tan | M | 59 |
Sun Yat-Sen University
| 22 Jahre |
Charles Sawyers | M | 65 |
Weill Cornell Graduate School of Medical Sciences
| 16 Jahre |
Mary Newman | F | 65 |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | - |
Nancy Hong | M | - |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | 3 Jahre |
Steven Tregay | M | - |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | - |
Yang Dajun | M | - |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | - |
Kevin Bitterman | M | 47 |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | - |
Jay K. Trautman | M | 65 |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | - |
Wen Chen | M | - |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Biao Yang | M | 44 |
Sun Yat-Sen University
| 6 Jahre |
Cheng Li | M | 40 |
Sun Yat-Sen University
| 6 Jahre |
Peiwen Yu | M | 54 |
Sun Yat-Sen University
| 2 Jahre |
Xiao Min Feng | F | 42 |
Sun Yat-Sen University
| 6 Jahre |
Cui Min Zou | M | 46 |
Sun Yat-Sen University
| 6 Jahre |
Shi Gang Deng | M | 51 |
Sun Yat-Sen University
| 10 Jahre |
Ling Xiang | M | 43 |
Sun Yat-Sen University
| 10 Jahre |
Yong Xu | M | 65 |
Sun Yat-Sen University
| 3 Jahre |
Rui Lu | M | 49 |
Sun Yat-Sen University
| 4 Jahre |
Xingshi Chen | M | 56 |
Sun Yat-Sen University
| 4 Jahre |
Wuzhen Guo | M | 56 |
Sun Yat-Sen University
| 1 Jahre |
Huaqiang Liu | M | 44 |
Sun Yat-Sen University
| 4 Jahre |
Weilin Li | M | 43 |
Sun Yat-Sen University
| 4 Jahre |
Jin Feng Huang | M | - |
Sun Yat-Sen University
| 4 Jahre |
Jian Xiong Zheng | M | 54 |
Sun Yat-Sen University
| 2 Jahre |
Zhibin Xu | M | 48 |
Sun Yat-Sen University
| 4 Jahre |
Le Qiang He | M | 44 |
Sun Yat-Sen University
| 4 Jahre |
Tian Chen | F | - |
Sun Yat-Sen University
| 4 Jahre |
Tian Wang | F | - |
Sun Yat-Sen University
| 4 Jahre |
Zhong Ping Deng | M | 47 |
Sun Yat-Sen University
| 1 Jahre |
Zhen Hao Lu | M | 45 |
Sun Yat-Sen University
| 3 Jahre |
Ying He | M | 55 |
Sun Yat-Sen University
| 2 Jahre |
Ying Jie Li | M | 41 |
Sun Yat-Sen University
| 4 Jahre |
Xun Qin Shi | M | 51 |
Sun Yat-Sen University
| 2 Jahre |
De Yong Yang | M | 50 |
Sun Yat-Sen University
| 2 Jahre |
Hong Huang | M | 46 |
Sun Yat-Sen University
| 4 Jahre |
Xin Qiu | M | 43 |
Sun Yat-Sen University
| 4 Jahre |
Yue Jun Li | M | 48 |
Sun Yat-Sen University
| 2 Jahre |
Vik Li | F | - |
Sun Yat-Sen University
| 4 Jahre |
Da Zhu | M | 43 |
Sun Yat-Sen University
| 4 Jahre |
Yu Wu | F | 47 |
Sun Yat-Sen University
| 3 Jahre |
Zhang Amy | F | - |
Sun Yat-Sen University
| 4 Jahre |
Hong Hai Zhu | M | 44 |
Sun Yat-Sen University
| 4 Jahre |
Ying Xiang | M | 56 |
Sun Yat-Sen University
| 3 Jahre |
Chun Chen | F | 47 |
Sun Yat-Sen University
| 3 Jahre |
Rong Sheng Chen | M | 51 |
Sun Yat-Sen University
| 3 Jahre |
Bo Liang | M | 44 |
Sun Yat-Sen University
| 4 Jahre |
Sheng Ye | M | 45 |
Sun Yat-Sen University
| 3 Jahre |
Xiao Lin Long | F | 41 |
Sun Yat-Sen University
| 4 Jahre |
Xinxin Deng | F | 48 |
Sun Yat-Sen University
| 4 Jahre |
Li Min Zhang | M | 69 |
Sun Yat-Sen University
| 10 Jahre |
Hong Tao Ning | M | 51 |
Sun Yat-Sen University
| 1 Jahre |
Yu Liu | M | - |
Sun Yat-Sen University
| 4 Jahre |
Jing Pu Gu | M | - |
Sun Yat-Sen University
| 3 Jahre |
Wan Li Yu | F | 46 |
Sun Yat-Sen University
| 4 Jahre |
Ling Zhi Ceng | F | 43 |
Sun Yat-Sen University
| 4 Jahre |
Xiao Feng Zhang | M | 47 |
Sun Yat-Sen University
| 4 Jahre |
Zhi Jiang Yan | M | 42 |
Sun Yat-Sen University
| 3 Jahre |
Chun Fai Kung | M | - |
Sun Yat-Sen University
| 1 Jahre |
Jin Gou Huang | F | 45 |
Sun Yat-Sen University
| 4 Jahre |
Jerry Ou | M | - |
Sun Yat-Sen University
| 4 Jahre |
Jin Hao Chen | M | 43 |
Sun Yat-Sen University
| 4 Jahre |
Song Hou | M | 48 |
Sun Yat-Sen University
| 4 Jahre |
Siu Wan C. Kong | F | 54 |
Sun Yat-Sen University
| 4 Jahre |
Yi Yang | M | 46 |
Sun Yat-Sen University
| 3 Jahre |
Yi Tan | M | 44 |
Sun Yat-Sen University
| 3 Jahre |
Zhi Bin Chen | M | 42 |
Sun Yat-Sen University
| 4 Jahre |
Shi Lian Xiao | M | 52 |
Sun Yat-Sen University
| 3 Jahre |
Lian Lu | M | 55 |
Sun Yat-Sen University
| 4 Jahre |
Hai Ming Rong | M | 47 |
Sun Yat-Sen University
| 4 Jahre |
Zhi Jun Liu | M | 60 |
Sun Yat-Sen University
| 2 Jahre |
Fan Mai | M | 45 |
Sun Yat-Sen University
| 3 Jahre |
Chao Yin | M | 40 |
Sun Yat-Sen University
| 4 Jahre |
Jin Feng Huang | M | 41 |
Sun Yat-Sen University
| 4 Jahre |
Yi Lun Liang | M | 47 |
Sun Yat-Sen University
| 4 Jahre |
Qi Ni Peng | F | 41 |
Sun Yat-Sen University
| 4 Jahre |
Yu Gang Lin | M | 55 |
Sun Yat-Sen University
| - |
Dan Wang | F | 52 |
Sun Yat-Sen University
| 2 Jahre |
Shao Bo Liu | M | 64 |
Sun Yat-Sen University
| 3 Jahre |
Jian Hua Zhou | M | 43 |
Sun Yat-Sen University
| 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
China | 76 | 77,55% |
Vereinigte Staaten | 22 | 22,45% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen